![]() The predominant cause of urinary tract infections is periurethral colonization of bacteria from a fecal reservoir, which then ascends the urinary tract. Nitrofurantoin is advantageous in this role as it concentrates in the lower urinary tract while maintaining a low serum concentration and also does not significantly affect bowel flora. ![]() Nitrofurantoin’s primary use has remained the treatment and prophylaxis of urinary tract infections. Increasing resistance to newer antibiotics coinciding with increasing prevalence of extended-spectrum beta-lactamase (ESBL) producing bacteria has led to a resurgence in use of nitrofurantoin. More recently, several major guidelines have declared nitrofurantoin as the first-line therapy for treatment of uncomplicated lower urinary tract infections. Nitrofurantoin was widely used the for treatment of lower urinary tract infections until the 1970s when trimethoprim-sulfamethoxazole and newer beta-lactam antibiotics became available. ![]() Nitrofurantoin is a synthetic antimicrobial created from furan and an added nitro group and a side change containing hydantoin. ![]() It is effective against most gram-positive and gram-negative organisms. Nitrofurantoin was approved by the FDA in 1953 for treatment of lower urinary tract infection. Nitrofurantoin is an antibiotic medication that is used for the treatment of uncomplicated lower urinary tract infection.
0 Comments
Leave a Reply. |